Pathological Response and Survival in Cervical Cancer Treatment
Author Information
Author(s): Candelaria Myrna, Chanona-Vilchis José, Cetina Lucely, Flores-Estrada Diana, López-Graniel Carlos, González-Enciso Aaron, Cantú David, Poitevin Adela, Rivera Lesbia, Hinojosa Jose, de la Garza Jaime, Dueñas-Gonzalez Alfonso
Primary Institution: Instituto Nacional de Cancerología, Mexico City
Hypothesis
More effective neoadjuvant modalities would produce longer survival by increasing the pathological complete response rates.
Conclusion
Complete pathological response but no near-complete and partial responses is associated with longer survival in cervical cancer patients treated with neoadjuvant chemotherapy or chemoradiotherapy.
Supporting Evidence
- 39.2% of patients achieved a complete pathological response.
- Overall survival was 98.3% in patients with complete response.
- Only 6.6% of patients with complete response relapsed.
Takeaway
If patients with cervical cancer have no cancer left after treatment, they live longer. But if there's still some cancer left, they don't live as long.
Methodology
Four cohorts of patients with locally advanced cervical carcinoma were analyzed for pathological response and survival after neoadjuvant chemotherapy or chemoradiation followed by radical hysterectomy.
Potential Biases
Potential selection bias due to the nature of the cohorts and treatment protocols.
Limitations
The study is limited by its retrospective nature and the specific patient population analyzed.
Participant Demographics
Mean age was 44.7 years, with almost two-thirds being FIGO stage IIB.
Statistical Information
P-Value
0.0001
Confidence Interval
95% CI: 1.103 - 1.953
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website